Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Papp

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
The British Journal of Dermatology|September 13, 2018
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibodyK A Papp, M Gooderham, R Jenkins, et al.
The British Journal of Dermatology|December 1, 2007
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisD Revicki, M K Willian, J-H Saurat, et al.
The British Journal of Dermatology|September 6, 2019
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studiesA B Kimball, K A Papp, K Reich, et al.
The British Journal of Dermatology|June 24, 2006
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trialL Dubertret, W Sterry, J D Bos, et al.
The British Journal of Dermatology|July 10, 2019
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trialA B Gottlieb, A Kubanov, M van Doorn, et al.
The British Journal of Dermatology|March 28, 2019
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumabA B Kimball, T Kerbusch, F van Aarle, et al.
Journal of Cutaneous Medicine and Surgery|May 10, 2002
Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosaceaJ K L Tan, C Girard, A Krol, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2021
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE studyW Gulliver, A Alavi, M C Wiseman, et al.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
The British Journal of Dermatology|September 13, 2018
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibodyK A Papp, M Gooderham, R Jenkins, et al.
The British Journal of Dermatology|December 1, 2007
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisD Revicki, M K Willian, J-H Saurat, et al.
The British Journal of Dermatology|September 6, 2019
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studiesA B Kimball, K A Papp, K Reich, et al.
The British Journal of Dermatology|June 24, 2006
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trialL Dubertret, W Sterry, J D Bos, et al.
The British Journal of Dermatology|July 10, 2019
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trialA B Gottlieb, A Kubanov, M van Doorn, et al.
The British Journal of Dermatology|March 28, 2019
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumabA B Kimball, T Kerbusch, F van Aarle, et al.
Journal of Cutaneous Medicine and Surgery|May 10, 2002
Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosaceaJ K L Tan, C Girard, A Krol, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 11, 2021
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE studyW Gulliver, A Alavi, M C Wiseman, et al.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
The British Journal of Dermatology|November 29, 2018
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesK Reich, K A Papp, A W Armstrong, et al.
Pageof 6